Safety and Efficacy of LCI699 in Cushing's Disease Patients

NCT01331239 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Cushings Disease
Cushing Disease

Interventions

DRUG: LCI699

Sponsor

Novartis Pharmaceuticals